Catálogo de publicaciones - revistas
Epilepsia
Resumen/Descripción – provisto por la editorial en inglés
Epilepsia is the leading, most authoritative source for current clinical and research results on all aspects of epilepsy.Palabras clave – provistas por la editorial
epilepsy; neurology; medicine; brain; seizure; temporal lobe; stroke; convulsions; article; periodia
Disponibilidad
| Institución detectada | Período | Navegá | Descargá | Solicitá |
|---|---|---|---|---|
| No detectada | desde ene. 1997 / hasta dic. 2023 | Wiley Online Library |
Información
Tipo de recurso:
revistas
ISSN impreso
0013-9580
ISSN electrónico
1528-1167
Editor responsable
John Wiley & Sons, Inc. (WILEY)
País de edición
Baréin
Fecha de publicación
1909-
Cobertura temática
Tabla de contenidos
doi: 10.1111/epi.17566
From Basic Sciences and Engineering to Epileptology: A Translational Approach
Elie Bou Assi
; Kaspar Schindler; Christophe de Bézenac; Timothy Denison; Sharanya Desai; Simon S. Keller; Émile Lemoine; Abbas Rahimi; Mahsa Shoaran; Christian Rummel
Palabras clave: Neurology (clinical); Neurology.
Pp. No disponible
doi: 10.1111/epi.17571
Diagnostic and therapeutic approaches in refractory insular epilepsy
Odile Feys; Serge Goldman; Valentina Lolli; Chantal Depondt; Benjamin Legros; Nicolas Gaspard; Sophie Schuind; Xavier De Tiège; Estelle Rikir
Palabras clave: Neurology (clinical); Neurology.
Pp. No disponible
doi: 10.1111/epi.17575
Comparing Electrical Stimulation Functional Mapping with Subdural Electrodes and
Stereo‐EEG
Gewalin Aungaroon; Kishore Vedala; Anna W. Byars; Brian Ervin; Leonid Rozhkov; Paul S. Horn; S. K. Z. Ihnen; Katherine D. Holland; Jeffrey R. Tenney; Kelly Kremer; Susan L. Fong; Nan Lin; Wei Liu; Todd M. Arthur; Hisako Fujiwara; Jesse Skoch; James L. Leach; Francesco T. Mangano; Hansel M. Greiner; Ravindra Arya
Palabras clave: Neurology (clinical); Neurology.
Pp. No disponible
doi: 10.1111/epi.17524
Neurostimulation in generalized epilepsy: A systematic review and meta‐analysis
Zulfi Haneef; Henry C. Skrehot
Palabras clave: Neurology (clinical); Neurology.
Pp. 811-820
doi: 10.1111/epi.17622
Predicting post‐traumatic epilepsy using admission electroencephalography after severe traumatic brain injury
Matthew Pease; Jonathan Elmer; Ameneh Zare Shahabadi; Arka N. Mallela; Juan F. Ruiz‐Rodriguez; Daniel Sexton; Niravkumar Barot; Jorge A. Gonzalez‐Martinez; Lori Shutter; David O. Okonkwo; James F. Castellano
Palabras clave: Neurology (clinical); Neurology.
Pp. No disponible
doi: 10.1111/epi.17632
Hemispherotomy in Children: A Retrospective Analysis of 152 Surgeries in a Single Center and Predictors for
Long‐Term
Seizure Outcome
Thilo Kalbhenn; Thomas Cloppenborg; Friedrich G. Woermann; Anne Hagemann; Tilman Polster; Roland Coras; Ingmar Blümcke; Christian G. Bien; Matthias Simon
Palabras clave: Neurology (clinical); Neurology.
Pp. No disponible
doi: 10.1111/epi.17555
Critical role of the ventral temporal lobe in naming
Kathryn M. Snyder; Kiefer J. Forseth; Cristian Donos; Patrick S. Rollo; Simon Fischer‐Baum; Joshua Breier; Nitin Tandon
Palabras clave: Neurology (clinical); Neurology.
Pp. 1200-1213
doi: 10.1111/epi.17656
A novel
KCNC1
gain‐of‐function variant causing developmental and epileptic encephalopathy: “precision medicine” approach with fluoxetine
Ambrosino Paolo; Ragona Francesca; Mosca Ilaria; Vannicola Chiara; Canafoglia Laura; Solazzi Roberta; Rivolta Ilaria; Freri Elena; Granata Tiziana; Messina Giuliana; Castellotti Barbara; Gellera Cinzia; Soldovieri Maria Virginia; DiFrancesco Jacopo Cosimo; Taglialatela Maurizio
Palabras clave: Neurology (clinical); Neurology.
Pp. No disponible
doi: 10.1111/epi.17661
The role of the orexin system in the bidirectional relation between sleep and epilepsy: new chances for patients with epilepsy by the antagonism to orexin receptors?
Chiara Berteotti; Carmen Calvello; Claudio Liguori
Palabras clave: Neurology (clinical); Neurology.
Pp. No disponible
doi: 10.1111/epi.17630
Epileptic spasms in CDKL5 deficiency disorder: Delayed treatment and poor response to first‐line therapies
Heather E. Olson; Scott Demarest; Elia Pestana‐Knight; Ahsan N. Moosa; Xiaoming Zhang; José R. Pérez‐Pérez; Judy Weisenberg; Erin O’Connor Prange; Eric D. Marsh; Rajsekar R. Rajaraman; Bernhard Suter; Akshat Katyayan; Isabel Haviland; Carolyn Daniels; Bo Zhang; Caitlin Greene; Michelle DeLeo; Lindsay Swanson; Jamie Love‐Nichols; Timothy Benke; Chellamani Harini; Annapurna Poduri
<jats:title>Abstract</jats:title><jats:sec><jats:title>Objective</jats:title><jats:p>We aimed to assess the treatment response of infantile‐onset epileptic spasms (ES) in CDKL5 deficiency disorder (CDD) vs other etiologies.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We evaluated patients with ES from the CDKL5 Centers of Excellence and the National Infantile Spasms Consortium (NISC), with onset from 2 months to 2 years, treated with adrenocorticotropic hormone (ACTH), oral corticosteroids, vigabatrin, and/or the ketogenic diet. We excluded children with tuberous sclerosis complex, trisomy 21, or unknown etiology with normal development because of known differential treatment responses. We compared the two cohorts for time to treatment and ES remission at 14 days and 3 months.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>We evaluated 59 individuals with CDD (79% female, median ES onset 6 months) and 232 individuals from the NISC database (46% female, median onset 7 months). In the CDD cohort, seizures prior to ES were common (88%), and hypsarrhythmia and its variants were present at ES onset in 34%. Initial treatment with ACTH, oral corticosteroids, or vigabatrin started within 1 month of ES onset in 27 of 59 (46%) of the CDD cohort and 182 of 232 (78%) of the NISC cohort (<jats:italic>p</jats:italic> < .0001). Fourteen‐day clinical remission of ES was lower for the CDD group (26%, 7/27) than for the NISC cohort (58%, 106/182, <jats:italic>p</jats:italic> = .0002). Sustained ES remission at 3 months occurred in 1 of 27 (4%) of CDD patients vs 96 of 182 (53%) of the NISC cohort (<jats:italic>p</jats:italic> < .0001). Comparable results were observed with longer lead time (≥1 month) or prior treatment. Ketogenic diet, used within 3 months of ES onset, resulted in ES remission at 1 month, sustained at 3 months, in at least 2 of 13 (15%) individuals with CDD.</jats:p></jats:sec><jats:sec><jats:title>Significance</jats:title><jats:p>Compared to the broad group of infants with ES, children with ES in the setting of CDD often experience longer lead time to treatment and respond poorly to standard treatments. Development of alternative treatments for ES in CDD is needed.</jats:p></jats:sec>
Pp. 1821-1832